{"subsection_name": "Money &amp; Policy", "pub_date": "2011-10-28T15:28:15Z", "byline": {"original": "By ANDREW POLLACK", "person": [{"lastname": "POLLACK", "organization": "", "rank": 1, "role": "reported", "firstname": "Andrew"}]}, "abstract": "The new treatments were approved only last spring.", "word_count": "625", "print_page": null, "news_desk": null, "snippet": "The new treatments were approved only last spring.", "multimedia": [], "source": "The New York Times", "blog": [], "keywords": [], "type_of_material": "Blog", "lead_paragraph": null, "web_url": "http://prescriptions.blogs.nytimes.com/2011/10/28/vertex-bests-merck-in-new-hepatitis-c-drug-sales/", "section_name": "Health", "headline": {"main": "Vertex Bests Merck in New Hepatitis C Drug Sales", "kicker": "Prescriptions Blog"}, "slideshow_credits": null, "_id": "54f3a7f638f0d8401891748c", "document_type": "blogpost"}